CLINICAL TRIALS AND OBSERVATIONS Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
نویسندگان
چکیده
1Department of Pediatrics and Bone Marrow Transplant Unit, University Hospital Schleswig-Holstein, Kiel, Germany; 2LWP Statistician, Research Institute, Hospital de la Sant Pau, Barcelona, Spain; 3Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium; 4Bone Marrow Transplant Unit, Schneider Children’s Medical Center of Israel, Petach-Tikva, Israel; 5Department of Pediatrics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6Oncology-Haematology & Cell Therapy Unit, University of Bologna, Bologna, Italy; 7Department of Hematology, Royal Free Hospital and School of Medicine, London, United Kingdom; 8Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel; 9Haematology & Immunology Pediatric Unit, Hôpital Robert Debre, Paris, France; 10Servicio de Hematologia, Hospital Universitario Virgen de las Nieves, Granada, Spain; 11Bone Marrow & Stem Cell Transplantation Clinic, King Hussein Cancer Centre, Amman, Jordan; 12Department of Pediatric Hematology, Royal Manchester Children’s Hospital, Manchester, United Kingdom; 13Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany; 14Institute G. Gaslini, Genova, Italy; 15Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; and 16Asklepios Klinik St Georg, Hamburg, Germany
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Nonmyeloablative stem cell transplantation in patients with follicular lymphoma has been designed to exploit the graftversus-lymphoma immunity. The longterm effectiveness and toxicity of this strategy, however, is unknown. In this prospective study, we analyzed our 8-year experience. Patients received a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
Autologous stem cell transplantation (ASCT) improves survival in patients with previously untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non-Hodgkin lymphoma (NHL). Lower relapse rates seen in allogeneic stem cell transplantation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-verus-tumor effect. In ASCT, th...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
We report the outcomes after reducedintensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n 41; high-grade NHL [HG-NHL], n 37; mantle cell lymphoma [MCL], n 10). Thirty-seven patients had previously received autografts, and 21 were in complete remission (CR) at transplantation. Conditioning therapy consisted of a...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
Rodrigo Martino, Simona Iacobelli, Ronald Brand, Thekla Jansen, Anja van Biezen, Jürgen Finke, Andrea Bacigalupo, Dietrich Beelen, Jossy Reiffers, Agnes Devergie, Emilie Alessandrino, Ghulam J. Mufti, Renée Barge, Jorge Sierra, Tapani Ruutu, Marc Boogaerts, Michele Falda, Jean-Pierre Jouet, Dieter Niederwieser, and Theo de Witte, for the Myelodysplastic Syndrome subcommittee of the Chronic Leuk...
متن کاملBrentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
IMPORTANCE The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of ...
متن کامل